Last reviewed · How we verify
abciximab bolus only regimen
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications in high-risk patients undergoing coronary angioplasty.
At a glance
| Generic name | abciximab bolus only regimen |
|---|---|
| Sponsor | Università degli Studi di Ferrara |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa integrin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Abciximab irreversibly binds to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, it prevents fibrinogen-mediated platelet cross-linking and clot formation. The bolus-only regimen delivers a single intravenous dose without subsequent infusion, providing rapid antiplatelet effects for acute coronary intervention.
Approved indications
- Acute coronary syndrome undergoing percutaneous coronary intervention
- Prevention of ischemic complications in high-risk patients undergoing coronary angioplasty
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
- Back pain
Key clinical trials
- Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI (PHASE4)
- Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- abciximab bolus only regimen CI brief — competitive landscape report
- abciximab bolus only regimen updates RSS · CI watch RSS
- Università degli Studi di Ferrara portfolio CI